ArticleESMO open2023

A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology.

S-E Al-Batran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.